Ocular Hypertension - Pipeline Review, H1 2018

Publication ID:

GMD0218099

Publication Date:

February 27, 2018

Pages:

124

Publisher:

Global 麻豆原创s Direct

Countries:

Global [1]

USD 2,000.00

Drug Pipeline [2]

Pharma & Healthcare [3]

Description:

Ocular Hypertension - Pipeline Review, H1 2018

Summary

Global 麻豆原创s Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global 麻豆原创s Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 14, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global 麻豆原创s Direct鈥檚 proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it鈥檚 most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
Ocular Hypertension - Overview
Ocular Hypertension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ocular Hypertension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ocular Hypertension - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Allergan Plc
Can-Fite BioPharma Ltd
D. Western Therapeutics Institute Inc
F. Hoffmann-La Roche Ltd
Ironwood Pharmaceuticals Inc
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Neurim Pharmaceuticals Ltd
NicOx SA
Novartis AG
Ocular Therapeutix Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd
Ocular Hypertension - Drug Profiles
(bimatoprost + timolol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(latanoprost + netarsudil mesylate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(latanoprost + timolol maleate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-9778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bamosiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimatoprost ocular insert - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimatoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IWP-953 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levobetaxolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGV-354 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-1653 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-470 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCX-667 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netarsudil mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omidenepag isopropyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRO-067 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRO-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7945 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepetaprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-639 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-0125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-0135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
timolol maleate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJO-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
travoprost XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ocular Hypertension - Dormant Projects
Ocular Hypertension - Discontinued Products
Ocular Hypertension - Product Development Milestones
Featured News & Press Releases
Dec 18, 2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
Nov 27, 2017: Santen Files for Manufacturing and 麻豆原创ing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)
Nov 16, 2017: Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
Oct 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa (netarsudil ophthalmic solution) 0.02%
Sep 20, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa (netarsudil ophthalmic solution) 0.02%
Sep 06, 2017: Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
Aug 08, 2017: Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer
Jul 19, 2017: Aerie Pharmaceuticals Reports Positive Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
May 15, 2017: Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa (netarsudil ophthalmic solution) 0.02%
May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting
Apr 12, 2017: Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%
Mar 15, 2017: D. Western Therapeutics Institute Announces Completion of Phase I Clinical Study with WP-1303
Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for Ocular Hypertension, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2018
Ocular Hypertension - Pipeline by Aerpio Therapeutics Inc, H1 2018
Ocular Hypertension - Pipeline by Allergan Plc, H1 2018
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2018
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2018
Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2018
Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
Ocular Hypertension - Pipeline by NicOx SA, H1 2018
Ocular Hypertension - Pipeline by Novartis AG, H1 2018
Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2018
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2018
Ocular Hypertension - Pipeline by Shire Plc, H1 2018
Ocular Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
Ocular Hypertension - Pipeline by Sylentis SAU, H1 2018
Ocular Hypertension - Pipeline by Taejoon Pharm Co Ltd, H1 2018
Ocular Hypertension - Dormant Projects, H1 2018
Ocular Hypertension - Dormant Projects, H1 2018 (Contd..1), H1 2018
Ocular Hypertension - Discontinued Products, H1 2018
Ocular Hypertension - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures
List of Figures
Number of Products under Development for Ocular Hypertension, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:

Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Allergan Plc
Can-Fite BioPharma Ltd
D. Western Therapeutics Institute Inc
F. Hoffmann-La Roche Ltd
Ironwood Pharmaceuticals Inc
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Neurim Pharmaceuticals Ltd
NicOx SA
Novartis AG
Ocular Therapeutix Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.